Explore 3 Stock Ideas & Industry Insights Download Free Report

GlycoMimetics Inc

Company price
None USD 0.00(0%)
Last update at 2025-07-17T13:08:44.127245Z
Market Cap
17.21M

Momentum Score

…

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.26
Low
3.53
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.07M
Debt / Equity
0.02
ROE
-90.72%
Net Debt
-40.98M
ROCE
-123.72%
Diluted EPS TTM
-0.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.69M -63.43M -51.03M -57.89M -48.27M
Net income -93.33M -63.14M -50.27M -54.12M -48.27M
Selling general administrative 19.09M 17.11M 16.74M 14.36M 11.41M
Gross profit 0.07M 1.16M 10.16M - 0.00M
Reconciled depreciation 0.21M 0.26M 0.27M 0.28M 0.28M
Ebit -47.61M -63.71M -51.78M -61.67M -51.78M
Ebitda -47.40M -63.45M -51.51M -61.39M -51.51M
Depreciation and amortization 0.21M 0.26M 0.27M 0.28M 0.28M
Operating income -47.40M -63.45M -51.51M -61.39M -51.51M
Other operating expenses 47.48M 64.61M 61.67M 61.39M 51.51M
Interest expense 46.64M 0.02M 0.00M 0.00M 0.00M
Interest income 0.71M 0.02M 0.48M 3.50M 3.23M
Net interest income 0.71M 0.02M 0.48M 3.50M 3.23M
Income tax expense 46.64M -0.28M -0.75M -3.78M 3.23M
Total revenue 0.07M 1.16M 10.16M 0.00M 0.00M
Total operating expenses 47.48M 64.61M 61.67M 61.39M 51.51M
Cost of revenue - - - - 0.00M
Total other income expense net 0.71M 0.02M 0.48M 3.50M 3.23M
Net income from continuing ops -46.69M -63.43M -51.03M -57.89M -48.27M
Net income applicable to common shares -46.69M -63.43M -51.03M -57.89M -48.27M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 45.32M 51.81M 94.35M 142.83M 167.97M
Other current assets 1.82M 2.84M 533.80M 1238.33M 4326.32M
Total liab 6.90M 8.88M 12.74M 14.61M 13.77M
Total stockholder equity 38.41M 42.93M 81.60M 128.22M 154.20M
Other current liab 5.23M 6.99M 8.72M 9.44M 8.71M
Common stock 0.06M 0.05M 0.05M 0.05M 0.04M
Capital stock 0.06M 0.05M 0.05M 0.05M 0.04M
Retained earnings -456.49M -419.59M -372.90M -309.47M -258.44M
Other liab - - - 0.26M -
Other assets 0.00M 0.00M 1.61M -0.00M 0.00M
Cash 41.79M 47.87M 90.25M 137.03M 158.20M
Total current liabilities 6.84M 8.88M 11.82M 12.43M 10.95M
Net debt -40.98M -46.95M -88.33M -134.22M -154.58M
Short term debt 0.74M 0.92M 1.00M 0.90M 0.80M
Short long term debt total 0.81M 0.92M 1.92M 2.82M 3.62M
Other stockholder equity 494.84M 462.46M 454.45M 437.64M 412.60M
Property plant equipment - 0.99M 1.95M 0.62M 0.82M
Total current assets 43.79M 50.71M 90.25M 138.27M 162.53M
Net tangible assets - 42.93M 81.60M 128.22M 154.20M
Net receivables 0.18M 0.14M 0.00M 0.00M 0.19M
Inventory - -0.14M -533.81M -1237.09M -4322.18M
Accounts payable 0.87M 0.97M 2.11M 2.09M 1.44M
Accumulated other comprehensive income - - - - -1.86M
Common stock total equity - - - 0.05M 0.04M
Retained earnings total equity - - - -309.47M -258.44M
Non currrent assets other 0.76M 0.10M 2.15M 1.61M 1.61M
Non current assets total 1.53M 1.10M 4.09M 4.56M 5.44M
Capital lease obligations 0.81M 0.92M 1.92M 2.82M 3.62M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.08M -0.01M -0.07M -0.14M -0.13M
Change to liabilities -1.14M 0.02M 1.38M 1.48M 0.57M
Total cashflows from investing activities -0.08M -0.01M -0.07M -0.14M -0.13M
Total cash from financing activities 4.16M 10.72M 18.14M 0.41M 129.45M
Change to operating activities -3.52M -1.18M 3.28M 0.02M 0.06M
Net income -46.69M -63.43M -51.03M -57.89M -48.27M
Change in cash -42.38M -46.78M -21.17M -51.72M 85.99M
Begin period cash flow 90.25M 137.04M 158.20M 209.92M 123.92M
End period cash flow 47.87M 90.25M 137.04M 158.20M 209.92M
Total cash from operating activities -46.46M -57.49M -39.24M -51.98M -43.33M
Issuance of capital stock 4.16M 10.70M 17.82M 0.00M 128.43M
Depreciation 0.21M 0.26M 0.27M 0.28M 0.28M
Sale purchase of stock - - 18.14M 0.41M 129.45M
Other cashflows from financing activities -0.08M 0.03M 0.32M 0.41M 1.02M
Change to netincome 4.69M 6.84M 6.90M 6.22M 4.59M
Capital expenditures 0.08M 0.01M 0.07M 0.14M 0.13M
Cash flows other operating - - 3.23M -2.07M -0.49M
Cash and cash equivalents changes - - -21.17M -51.72M 85.99M
Change in working capital -4.66M -1.17M 3.93M -1.21M 0.08M
Stock based compensation 3.86M 6.09M 6.90M 6.22M 4.59M
Other non cash items 0.83M 0.75M 0.68M 0.62M 0.00M
Free cash flow -46.54M -57.50M -39.31M -52.13M -43.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

9708 Medical Center Drive, Rockville, MD, United States, 20850

240 243 1201

35

Name Title Year Born
Mr. Harout Semerjian CEO, Pres & Director 1970
Mr. Brian M. Hahn Sr. VP & CFO 1974
Dr. John L. Magnani Ph.D. Sr. VP of Research & Chief Scientific Officer 1953
Ms. Stephanie R. Irish CPA VP of Accounting 1971
Mr. Christian Dinneen-Long VP, Corp. Counsel & Corp. Sec. NA
Mr. Armand Girard Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. 1969
Mr. Bruce Johnson Sr. VP & Chief Commercial Officer NA
Dr. Edwin Rock M.D., Ph.D. Chief Medical Officer NA
Mr. Harout Semerjian CEO, President & Director 1970
Ms. Rachel K. King Co-Founder & Director 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…